Nexus Pharmaceuticals · PAI Pharma
PAI Pharma to buy Nexus Pharmaceuticals

FDA turns down Summit’s ivonescimab application. 3 acquisitions, 5 funding rounds, 2 PDUFA dates, 2 officer changes.
FDA signed a complete response letter a day before Summit Therapeutics’ Nov. 14 goal date for ivonescimab plus chemotherapy in advanced EGFR-mutated nonsquamous non-small cell lung cancer after an EGFR tyrosine kinase inhibitor.[4][1] Summit’s 8-K said the application “cannot be approved in its present form”; FDA questioned whether the progression-free survival result applied to U.S. patients, noted no statistically significant overall survival gain and recommended a new multiregional trial.[5][1] Cytokinetics had the same goal date but asked “to include the results of MAPLE-HCM” in the MYQORZO (aficamten) label for symptomatic obstructive hypertrophic cardiomyopathy.[6][7] The approved update, disclosed Nov. 16, adds head-to-head data against metoprolol without changing the indication.[8][9][7]
Neurosterix raised $105 million in a Series B mainly to take its muscarinic M4 modulator NTX-253 from Phase 1 into Phase 2 in schizophrenia.[2] Oyster Therapeutics was a step earlier: its $60 million Series A-2, led by a London life sciences fund, is meant to bring an oral tau degrader for Alzheimer’s and related diseases into the clinic.[2][3] Neurosterix’s lead investor also took part in Zai Lab’s roughly $250 million private placement, which closed Oct. 27 and was reported in a Nov. 9 Form D.[2][10][11][12] Zai Lab said the proceeds would mainly support zocilurtatug pelitecan, its antibody-drug conjugate in Phase 3 for previously treated small cell lung cancer.[10][13]
Lineage Cell Therapeutics took the acquisition route in neuroscience, buying NeuroAirmid Therapeutics, whose founding president Leslie Thompson led the research behind HUNT1, a Phase 1b/2a neural stem cell therapy for Huntington’s disease.[14][15] The largest figure in the 8-K is contingent: up to $48 million in clinical and regulatory milestones, against about $4.7 million in closing cash and stock for sellers and their expense fund, $1.7 million for third-party obligations and up to $5.4 million at the first anniversary.[16] Lineage previously acquired OPC1, a cell therapy for spinal cord injury, in a 2019 merger.[17][18]
AstraZeneca also returned to a familiar field, buying Omniose, led by Timothy Cooke, for its preclinical bacterial vaccine platform after a three-year collaboration and a 2024 acquisition that added a Phase 3-ready respiratory vaccine candidate.[19][20][21] PAI Pharma added more than 20 marketed hospital injectables by buying Nexus Pharmaceuticals, led by Stephen Kim, after a prior deal brought in aseptic manufacturing capacity in Sacramento.[22][23] Neither deal announcement disclosed a price.[22][24]
Acurx Pharmaceuticals said Joseph C. Scodari would retire from its board effective Nov. 13 and remain a corporate adviser.[25] Stryker’s Nov. 9 filing said it elected James E. Davis to a newly created board seat effective Jan. 1, 2027.[26]
PAI Pharma to buy Nexus Pharmaceuticals
Lineage Cell Therapeutics, Inc. to buy NeuroAirmid Therapeutics, Inc.
AstraZeneca to buy Omniose
Undisclosed of $29.9M
Series B of $105M
Undisclosed of $6.0M
Series A of $60.0M
Undisclosed of $250M
FDA goal date for ivonescimab (BLA)
FDA goal date for MYQORZO (sNDA), for hypertrophic cardiomyopathy
Change in directors or officers
Change in directors or officers